Fluticasone Propionate + Azelastine
Flutispray™ Plus: Each spray delivers Fluticasone Propionate BP 50 meg and Azelastine hydrochloride BP 137 meg.
Flutispray™ Plus is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 6 years of age and older who require treatment with both Azelastine Hydrochloride and Fluticasone Propionate for symptomatic relief.
Dose and Administration:
The recommended dosage of Flutispray™ Plus is one spray in each nostril twice daily.
Flutispray™ Nasal Spray: Each spray contains
Fluticasone Propionate BP 50 meg.
Flutispray™ is indicated for the management of the nasal symptoms of seasonal & perennial allergic & non-allergic rhinitis in adults and paediatric patient 4 years of age and older.
Dose & Administration:
Adults 02 (two) sprays in each nostril once daily, preferably in the morning.
In some cases, 02 (two) sprays in each nostril twice daily may be required or as directed by the physician.
Total daily doses of 200 meg (04 sprays) should not generally be exceeded.
Children (4 to 11 years of age) 01 (one) spray in each nostril once daily. In some cases, 01 (one) spray in each nostril twice daily may be required or as directed by the physician.
Total daily doses of 100 meg (2 sprays) should not generally be exceeded or as directed by the physicians
Ferric Iron (As Ferric Citrate)
Phoscon™ Tablet: Each film coated tablet contains Ferric Citrate INN equivalent to Ferric Iron 210 mg.
• The control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis
• The treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis
Dose & Administration:
Hyperphosphatemia in Chronic Kidney Disease on Dialysis:
• Starting dose is 2 tablets orally 3 times per day with meals
• Adjust dose by 1 to 2 tablets as needed to maintain serum phosphorus at target levels, up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
Iron DeficiencyAnemia in Chronic Kidney Disease not on Dialysis:
• Starting dose is 1 tablet orally 3 times per day with meals
• Adjust dose as needed to achieve and maintain hemoglobin goal, up to a maximum of 12 tablets daily or as directed by the physician.
Meltix™ Tablet: Each film coated tablet contains Flupentixol
Dihydrochloride BP equivalent to 0.5 mg Flupentixol and Melitracen Hydrochloride INN equivalent to 10 mg Melitracen.
It is indicated in various types of anxiety, depression and apathy.
These include-) Psychogenic depression
a. Depressive neurosis
b. Masked depression
c. Psychosomatic affections accompanied by anxiety and apathy.
d. Menopausal depressions
e. Dysphoria and depression in alcoholics and drug-addicts.
Dosage & Administration:
Adults : Usually 2 tablets daily at morning and noon. In severe cases the
morning dose may be increased to 2 tablets.
Elderly patients : 1 tablet in the morning.
Maintenance dose : Usually 1 tablet in the morning. In cases of insomnia or severe restlessness additional treatment with a sedative in acute phase is recommended. Or as directed by the physician.
Flubiotic 250 Capsule: Each capsule contains flucloxacillin sodium BPequivalent to 250 mg flucloxacillin.
Flubiotic 500 Capsule: Each capsule contains flucloxacillin sodium BPequivalent to 500 mg flucloxacillin.
Flubiotic Powder for Syrup: Each 5 ml reconstituted syrup contains flucloxacillin sodium BP equivalent to 125 mg flucloxacillin.
Flucloxacillin is indicated for the treatment of infections due to gram positive organisms,
(including infections caused by beta-lactamase producing staphylococci).
Dosage and Administration
Oral dosage should be administered half to one hour before meal or two hour after meal.Usual adult dose (including elderly patients): Oral 250 mg four times daily. Dosage may be
doubled in severe infections. Osteomyelitis, endocarditis: up to 8 gm daily in divided doses (6 to 8 hourly) or as directed by the physician.
Odafen™ 120: Each film coated tablet contains Fexofenadine
Hydrochloride USP 120 mg.
Odafen™ 180: Each film coated tablet contains Fexofenadine
Hydrochloride USP 180 mg.
Odafen™ Suspension: Each 5 ml suspension contains Fexofenadine Hydrochloride USP 30 mg.
Seasonal Allergic Rhinitis:
Odafen™ tablet are indicated for the relief of symptoms
associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Odafen™ oral suspension is indicated for the relief of symptoms associated with seasonal allergic rhinitis in children 2 to 11 years of age. Symptoms to treat
sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes.
Chronic Idiopathic Urticaria:
Odafen™ of Chronic Idiopathic Urticaria in adults and children 6 years of age and
Odafen™ manifestations of Chronic Idiopathic Urticaria in children 6 months to 11 years
of age. Fexofenadine Hydrochloride significantly reduces pruritus and the number
Imigra™ 5 Tablet: Each film coated tablet contains Flunarizine Dihydrochloride BP equivalent to 5 mg Flunarizine.
Imigra™ 10 Tablet: Each film coated tablet contains Flunarizine Dihydrochloride BP equivalent to 10 mg Flunarizine.
Imigra™ 5 Capsule: Each capsule contains Flunarizine Dihydrochloride BP equivalent to 5 mg Flunarizine.
Imigra™ 10 Capsule: Each capsule contains Flunarizine Dihydrochloride BP equivalent to 10 mg Flunarizine
O Symptomatic treatment of vestibular vertigo & dizziness.
O Peripheral vascular diseases (Intermittent claudication, Raynaud's phenomenon, paresthesia, cold extremities etc.).
O Epilepsy resistant to conventional anti-epileptic therapy.
O Prophylaxis of classic (with aura) or common (without aura) migraine.
Dose and Administration
For vertigo: The recommended maximum daily dose of Flunarizine in the treatment of vertigo is 10 mg daily in adults and 5 mg daily in children (<40 kg).
For epilepsy: An optimal therapeutic dosage in epileptic patients receiving other anti-epileptic drug is 15 mg to 20 mg daily in adults and 5 to 10 mg daily in children.
For migraine prophylaxis: Starting dose is 10 mg daily at night for adult patients less than 65 years of age and 5 mg daily for patients older than 65 years.
Maintenance treatment: If a patient's response is satisfactory and if a maintenance treatment is needed, the dose should be decreased. The patient should have 5 days treatment in a week at the same daily dose and 2 successive drug free days. Treatment should be stopped after 6 months and reinitiated only if the patient relapses.
Or as directed by the physician